Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of therapeutic cancer vaccines, is pleased to announce the following:
Result of Annual General Meeting
All resolutions proposed at the Annual General Meeting held earlier today were duly passed.
Result of General Meeting
All resolutions proposed at the General Meeting held earlier today were duly passed. Following the passing of the resolutions the Company can now proceed with the subdivision of each Existing Ordinary Share of 1p into 10 new Ordinary Shares of 0.1p each (the “Subdivision”) and the placing to raise £1.73 million, before costs, by means of the issue of 34,575,410 new Ordinary Shares at 5 pence per share (the “Placing”) to fund the working capital of the Company.
The Company has made an application to the London Stock Exchange and it is expected that Admission of the new Ordinary Shares and the Placing Shares will take place on 26 July 2011.
Following Admission, the Company will have a single class of shares being Ordinary Shares of 0.1 pence each and there will be 194,093,310 Ordinary Shares in issue, each carrying one vote per Ordinary Share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company's Ordinary Shares will be 194,093,310 and this number may be used by shareholders as the denominator in calculations to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.
Definitions in this announcement are consistent with those set out in the Circular issued to shareholders of the Company and dated 30 June 2011, a copy of which is available on the Company's website.
Scancell Holdings Plc
Professor Lindy Durrant/Dr Richard Goodfellow + 44 (0)207 245 1100
Adam Reynolds/Guy McDougall + 44 (0)207 245 1100
Zeus Capital - Nominated Adviser
Ross Andrews/Tom Rowley + 44 (0)161 831 1512
XCAP Securities Plc - Broker
John Belliss/Parimal Kumar +44 (0) 207 101 7070
It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia
Mon, 08 Apr 2019 08:20:00
The US patent covers Modi-1, while the European patent relates to a monoclonal antibody called FG88
Wed, 20 Mar 2019 07:55:00
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Tue, 12 Feb 2019 15:07:00
Sign up to our newsletter to stay up to date with Scancell